Role of EpiCor® in the body

The #1 postbiotic brand, EpiCor ® postbiotic is a fully fermented food clinically proven to support immune and gut health. It is made through a specialized fermentation process that produces a unique trace of metabolites including proteins, peptides, antioxidants, polyphenols, organic acids, nucleotides, polysaccharides (1-3 1-6, beta glucans) and mannan. When taken daily, EpiCor ® postbiotic works as a multivitamin for the immune system ®.

Impact of EpiCor® on the immune system

EpiCor® is a safe and natural anaerobic dry fermentation product from the fungus Saccharomyces cerevisiae that has been shown to act as an immunomodulator while helping to reduce gastrointestinal and possibly systemic inflammation in humans. EpiCor® ensures a consistent composition of bioactive metabolites including antioxidants, proteins, polysaccharides, vitamins, minerals and other nutrients.

The effects of EpiCor® on immunity include:

 

a. Anti-oxidant and anti-inflammatory: EpiCor® inhibits the formation of reactive oxygen species (ROS) and chemotactic transfer of the inflammatory mediator Leukotriene B4 in polymorphonuclear leukemic cells (polymorphonuclear (PMN) in humans.

The polymorphonuclear leukocyte type is abundant in the blood circulation and usually comprises 50–70% of the total number of circulating white blood cells. These cells are short-lived and have the ability to rapidly participate in proinflammatory immune defense mechanisms such as the production of antimicrobial free radicals, signaling between proinflammatory cells, and chemotactic transfer to inflammatory mediators that stimulate other cells to participate in inflammatory tissue sites.

Inhibition of oxidative radical formation was observed in polymorphonuclear leukemic cells when the cells were pretreated with EpiCor® dry fermentation fluid under oxidative stress.

Since several oxidants play a role in cell signaling, EpiCor® has the potential to reduce the background effects of chronic inflammation, thereby increasing the ability to maintain balanced immune responses.

b. Increase levels of secretory IgA immunoglobulins (sIgA) – antibodies that play an important role in mucosal immunity. Mucosal immunity is a part of the immune system that protects various mucous membranes against invasion by pathogenic bacteria and increases the production of IgG antibodies.

c. Stimulate immune cells: Proliferation of B lymphocytes and T lymphocytes – 2 types of white blood cells that play an important role in the immune system. Activation of natural killer (NK) cells.

d. Allergy relief: EpiCor® reduces allergy symptoms by reducing IgE – antibodies involved in the allergic process. The EpiCor®  group was also observed to reduce eosinophils in the nose, a type of white blood cell that is often elevated in environmentally sensitive healthy people.

Impact of EpiCor® on digestion

In addition to improving immunity, a recent study using in vitro intestinal models has shown that EpiCor® fermenter is selectively fermented by the intestinal microbiota in the colon, leading to beneficial regulation of gut microbiota and intestinal lumen environment.

These findings suggest that repeated administration of EpiCor® fermenters can positively affect the intestinal environment in humans, thereby increasing gastrointestinal comfort. The Human Intestinal Microbial Ecosystem Simulator (SHIME®) has shown that EpiCor® fermenter has prebiotic potential by increasing butyrate levels in the simulated colon and stimulating the growth of Lactobacilli.

Lactobacillus is also recognized to contain several health-promoting species. Butyrate, one of the major end products from the fermentation of carbohydrates by the intestinal microbiota, is the main source of energy for colon cells. It has been recognized for its immunomodulatory activity and anticancer effects, as well as for improving constipation and digestive problems.

A randomized placebo-controlled double-blind pilot study showed that EpiCor® significantly improved symptoms such as bloating/distention (p=0.033 and p=0.024 after 2 and 4 weeks of intervention, respectively), satiety (p=0.004 and p=0.023 after 2 and 4 weeks of using the intervention, respectively).

A significant improvement in stool consistency was observed for the entire population (p=0.023 after 2 weeks of intervention) as well as for the severe constipation group (p=0.046 after 2 weeks of intervention) and the frequency of bowel movements almost significantly increased for the whole subject (p=0.083 and p=0.090 after 2 and 4 weeks of intervention, respectively).

An increase in bacteria of the Bacteroidaceae and Prevotellaceae families previously reported to be deficient in patients with constipation was also detected in the group of severely constipated patients receiving EpiCor®.

Overall, these in vitro results indicate that long-term use of EpiCor® fermenter (up to 4 weeks) can modulate the intestinal environment and alter gut microbiota composition, thus showing important prebiotic-like effects.

Although used at a relatively low dose (500mg/day), especially when compared with the recommended dose for prebiotic fiber, EpiCor® improves gastrointestinal discomfort and constipation by modulating the gut microbiota to mimic prebiotic properties.

References:

[1] Possemiers et al., “A dried yeast fermentate selectively modulates both the luminal and mucosal gut microbiota and protects against inflammation, as studied in an integrated in vitro approach”, J Agric Food Chem, vol 61, no. 39, p 9380–9392, October 2013, doi: 10.1021/jf402137r.

[2] G. S. Jensen, S. G. Carter, S. G. Reeves, L. E. Robinson, and K. F. Benson, “Anti-Inflammatory Properties of a Dried Fermentate In Vitro and In Vivo”, J Med Food, vol. 18, p. 3, p. 378–384 , March 2015, doi: 10.1089/jmf.2013.0158.

[3] G. S. Jensen, A. N. Hart, and A. G. Schauss, “An antiinflammatory immunogen from yeast culture induces activation and alters chemokine receptor expression on human natural killer cells and B lymphocytes in vitro”, Nutrition Research, vol. 27, no. 6, p. 327–335, June 2007, doi: 10.1016/j.nutres.2007.04.008.

[4] M. A. Moyad et al., “Immunogenic yeast-based fermentation product reduces allergic rhinitis-induced nasal congestion: a randomized, double-blind, placebo-controlled trial”, Adv Ther, vol 26, no. 8, p. 795–804 , August 2009, doi: 10.1007/s12325-009-0057-y.

Source: Nutrition Research and Development Institute (https://inrd.vn/)

Read related articles at: https://ancarepharma.com/chu-de/kien-thuc-dinh-duong/

For specific advise, please contact us: https://www.facebook.com/ancarepharma/